Skip to content
OpenCapital
Get started

Monte Rosa Therapeutics, Inc. GLUE Proceeds From Underwritten Public Offering

Other financials

Income statement

See full
Revenue$4.2M-95.0%
Operating income-$50.0M-214%
Net income-$44.5M-195%
EPS (diluted)-$0.45-179%

Balance sheet

See full
Cash & equivalents$159.9M+104%
Total debt$39.1M-6.7%
Total equity$521.9M+89.7%
Total assets$736.4M+87.3%

Cash flow

See full
Operating cash flow-$37.4M+17.9%
CapEx$1.9M+17.7%
Free cash flow-$39.2M+16.7%

Valuation

See full
Market cap$1.76B+361%
Enterprise value$1.64B+381%
P/S41×+38.6×

Profitability

See full
Operating margin-345.2%—
Net margin-302.6%—
FCF margin-45.8%-64.9pp

Returns & leverage

See full
Return on equity-32.6%—
Debt / equity0.1×-0.1×
Current ratio9.5×+3.9×

Where this comes from

Reported directly by Monte Rosa Therapeutics, Inc. in its filing.

Tagged under the XBRL concept glue:ProceedsFromUnderwrittenPublicOffering.

The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monte Rosa Therapeutics, Inc.'s proceeds from underwritten public offering.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Monte Rosa Therapeutics, Inc.'s proceeds from underwritten public offering?
Monte Rosa Therapeutics, Inc. (GLUE) reported proceeds from underwritten public offering of $324.3M in Q1 2026.